Answers are grounded in this paper and cite their sources.
BackgroundNo randomized trial has compared Bruton tyrosine kinase inhibitor (BTKi)-based therapy with chemoimmunotherapy (CIT) in frontline Waldenström macroglobulinemia (WM); the RAINBOW trial (NCT04061512) is ongoing.Real-world data are therefore the only current evidence, particularly for older adults, who make up most patients and are underrepresented in trials.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: